



Annual General Meeting 2023

May 25, 2023
Company update by
Oncopeptides CEO Monica Shaw

Oncopeptides: value drivers



**Pepaxti: a proven
concept**



**Leading with
purpose**



**Proven and
promising**



**Treatment without
compromise**



**Financially
disciplined**

The experience and expertise for commercial excellence in multiple myeloma



Monica Shaw

Chief Executive Officer

Bachelor of Medicine/Surgery (MBBS), 15+ products launched, across multiple companies and geographies



Sofia Heigis

Chief Commercial Officer

Master in Pharmacology, launched 9+ products at AstraZeneca, 15+ years in pharma industry



Holger Lembrér

Chief Financial Officer

CFO experience from a global organization, 15+ years of accounting and finance experience



Jakob Lindberg

Chief Scientific Officer

10+ years at Oncoceptides
Medical License in Molecular Immunology,
Master of Science in pre-clinical medicine



Sara Svärdgren

Head of Human Resources

Previously in the financial industry, 10+ years of managerial and leadership experience



David Augustsson

Director of Corporate Affairs

Experience leading communication at a global financial technology company, 15+ years of corporate communication experience



Eva Nordström

Chief Operating Officer

10+ years at Oncoceptides, previously Pharmacia and AstraZeneca

Multiple myeloma remains a disease with unmet need



“Patients with advanced MM are often not fit and **suffer from side effects of previous treatments.**”

– **Maria-Victoria Mateo**,
Head Of Clinical Trial Unit and Myeloma Program Director,
University of Salamanca, Spain, HORIZON study investigator/author and LIGHTHOUSE lead investigator



“Patients in later lines and RRMM are by definition **heavily pre-treated**, so effective therapy that does not impact quality of life to a greater extent than necessary is clearly an advantage.”

– **Paul Richardson**,
Professor Of Medicine, Harvard Medical School,
Member of Oncopeptides Clinical Advisory Board, Lead author of HORIZON study



“For patients in later treatment lines, it gets more **challenging to ensure disease control** over a meaningful duration of time.”

– **Fredrik Schjesvold**,
Head Of Myeloma Center at Oslo University Hospital, Lead author of OCEAN study

A meaningful difference in multiple myeloma



- ✓ Offers patients with triple class refractory (TCR) multiple myeloma (MM) an opportunity to switch to an untapped and **new mode of action**
- ✓ Demonstrated clinically meaningful **efficacy** in heavily pre-treated relapsed refractory multiple myeloma (RRMM) patients who are TCR
- ✓ The **safety** profile consists primarily of adverse events that are predictable and manageable
- ✓ Over time, treatment with melflufen may sustain or improve health-related **quality of life** in patients with TCR MM

Differentiated go to market approach



Targeted country roll out to maximize profitability



Focused field force with mix of science and business background



Centralized marketing, medical and market access support to optimize costs



Strong value proposition for Pepaxti at competitive cost compared to competitors




Mix of self-commercialization and distributor model allows selected investment and optimized P&L

Journey from marketing authorization to commercial use and uptake in European markets



Payer led timeline

Our expanding European footprint matches our commercial opportunity



Increased presence on the ground to drive Pepaxti awareness




ONKORAT




9th Heidelberg Myeloma Workshop

Post-ASH 2023
Highlights der ASH-Jahrestagung

Veranstaltung
Perspektive in der Hämato-Onkologie



Continuing to progress our two pipeline platforms



PDC, Peptide Drug Conjugate; SPiKE, Small Polypeptide based innate Killer Engager.




Press release

Oncopeptides receives a research grant from Sweden's Innovation Agency to explore the PDC platform in solid tumors

March 28, 2023

Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company has received a research grant of 3 MSEK from Sweden's Innovation Agency (Vinnova), to explore the



Press release

Oncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myeloma

September 7, 2022

STOCKHOLM — September 7, 2022 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the company has received a research grant of 5 MSEK from Sweden's Innovation Agency, to develop preclinical proof of concept (PoC) for a novel synthetic small polypeptide for the treatment of multiple myeloma. The compound is a Natural Killer (NK) cell engaging immunotherapy, with superior tissue penetration and immune cell activation. The NK ENGAGE project has been qualified as a Eurostars program and will be driven by a

Our goals in 2023

- Financial discipline
- Launch success in Germany and Phase I markets
- Geographic expansion
- Pipeline progression
- People and culture